Hunting for next big eye disease drug, Regeneron gets deeper into gene therapies with ViGeneron pactnews2022-04-06T10:49:19+00:00April 6th, 2022|FierceBiotech|
Merck looks to cardiovascular pipeline for $10B+ peak sales—and diversification from Keytrudanews2022-04-05T21:29:45+00:00April 5th, 2022|FierceBiotech|
Merck looks to cardiovascular pipeline for $10B-plus peak sales—and diversification from Keytrudanews2022-04-05T21:29:45+00:00April 5th, 2022|FierceBiotech|
Big Pharma partnerships, record $22.7B investment raise profile of regenerative medicine in 2021news2022-04-05T17:56:28+00:00April 5th, 2022|FierceBiotech|
String of NIH departures continues as Ned Sharpless, head of the National Cancer Institute, steps downnews2022-04-05T13:54:34+00:00April 5th, 2022|FierceBiotech|
Takeda’s gene therapy hunger not yet quelled as Evozyne pact extended for $400M in biobucksnews2022-04-05T13:02:03+00:00April 5th, 2022|FierceBiotech|
Phase 3 rare disease failure extends Theravance’s losing streaknews2022-04-05T12:38:00+00:00April 5th, 2022|FierceBiotech|
Imara flunks phase 2b trials in sickle cell and thalassemia, wiping out clinical pipelinenews2022-04-05T11:48:58+00:00April 5th, 2022|FierceBiotech|
Rough biotech market won’t stop 5AM Ventures’ new $750M life science fundsnews2022-04-04T21:23:19+00:00April 4th, 2022|FierceBiotech|
As FDA funding debated, CDER chief makes a pitch for more scientists—not a reorganizationnews2022-04-04T21:18:28+00:00April 4th, 2022|FierceBiotech|
